Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Okusaka T, Ueno H, Morizane C, Kondo S, Sakamoto Y, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M. Okusaka T, et al. Among authors: sakamoto y. J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):628-33. doi: 10.1002/jhbp.257. Epub 2015 May 3. J Hepatobiliary Pancreat Sci. 2015. PMID: 25940377 Review.
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Ikeda M, Shiina S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Ueno H, Morizane C, Kondo S, Sakamoto Y, Asaoka Y, Tateishi R, Koike K, Arioka H, Okusaka T. Ikeda M, et al. Among authors: sakamoto y. Invest New Drugs. 2014 Oct;32(5):928-36. doi: 10.1007/s10637-014-0109-2. Epub 2014 May 15. Invest New Drugs. 2014. PMID: 24829073 Free PMC article. Clinical Trial.
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Tanaka H, Mitsunaga S, Kobayashi M, Funazaki H, Katayama S, Kuwahara A, Okuyama H, Takahashi H, Ohno I, Shimizu S, Sakamoto Y, Kondo S, Morizane C, Ueno H, Okusaka T, Ochiai A, Ikeda M. Tanaka H, et al. Among authors: sakamoto y. Gan To Kagaku Ryoho. 2015 Mar;42(3):313-7. Gan To Kagaku Ryoho. 2015. PMID: 25812499 Japanese.
[The excision repair cross-complementation group 1].
Sakamoto Y, Ojima H, Morizane C, Kanai Y, Okusaka T. Sakamoto Y, et al. Nihon Rinsho. 2015 Mar;73 Suppl 3:485-90. Nihon Rinsho. 2015. PMID: 25857073 Japanese. No abstract available.
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M, Shimada Y, Ichikawa H, Kato M, Shibata T, Morizane C, Sakamoto Y, Shimada K, Komatsu Y, Sakamoto N, Okusaka T. Hayashi H, et al. Among authors: sakamoto y, sakamoto n. Pancreas. 2017 Mar;46(3):335-340. doi: 10.1097/MPA.0000000000000760. Pancreas. 2017. PMID: 28099251
3,454 results